Fundraising Fox
Egle Therapeutics
Founded 2020 · 52 employees on LinkedIn · 4 known investors
Find your way into Egle Therapeutics
Sign up to see every warm intro you have to Egle Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Egle Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.
Founders & leadership
Board
Investors · 4
How we know: the company's own site · a partner's Signal profile · Not right? Tell us
How we know: Fund+'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
Founder mafia
2 people who came through Egle Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Egle Therapeutics do?
- Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.
- Who are Egle Therapeutics's investors?
- Egle Therapeutics's investors include EQT Life Sciences, Fund+, JDRF T1D Fund, Bioqube Ventures.